September 9th 2025
Real-world evidence supports neffy as comparable to epinephrine injection in anaphylaxis care.
Omalizumab outperforms oral immunotherapy in treating multi-food allergy
March 27th 2025A new clinical trial has found that omalizumab (Xolair; Genetech, Novartis) is more effective than oral immunotherapy (OIT) in treating multi-food allergy in individuals with severe allergic reactions to small amounts of common food allergens.
DB-OTO demonstrates improved hearing in 10 of 11 children with profound genetic hearing loss
February 24th 2025Updated data from the phase 1/2 CHORD trial in 12 children with profound genetic hearing loss were presented at the Association for Research in Otolaryngology’s 48th Annual MidWinter Meeting.
Dupilumab (Dupixent) becomes first FDA-approved drug for adolescent CRSwNP
September 13th 2024The landmark indication is supported by a couple of pivotal trials assessing dupilumab for patients with chronic rhinosinusitis with nasal polyps, as well as a pediatric severe asthma trial assessing the biologic.